H19 in Acute Lymphoblastic Leukemia.

Assiut University

Status: Not yet enrolling

Conditions: Acute Lymphoid Leukemia

Study type: Observational

Funder types: Other

Identifiers

NCT05943093

PCR in acute leukemia

Details and patient eligibility

About

• Study the expression level of H19 gene in the samples from ALL patients by real-time PCR.
• Correlate the expression level of H19 gene with the clinical presentation and laboratory data of those patients.

Full description

Acute lymphoblastic leukemia (ALL) is the most common cancer affecting children and adolescents (Zeng XL et al, 2023). ALL is a haematological malignancy characterized by the malignant clonal expansion of lymphoid hematopoietic precursors (Hong Z et al, 2021). It arises from B- or T-lineage lymphoid progenitors: B-cell-precursor ALL (B-ALL) and T-cell ALL (T-ALL) (Brady SW et al., 2022). Rrelapse in ALL is the fundamental cause of treatment failure in 15-20% of patients (Hulleman E et al, 2009). Therefore, the exploration of novel functional molecules that play a role in ALL pathogenesis could be effective therapeutic targets for this disease (Asadi M et al, 2023).

Long non-coding RNAs (lncRNAs) are non-protein coding transcripts longer than 200 nucleotides (Kopp F et al, 2018). H19 was the first lncRNA to be discovered and submitted for genomic imprinting (Yoshimura H et al, 2018). It has a role in embryogenesis and tumorigenesis (Yoshimura H et al, 2014). It also has an indispensable role in enhancing cell proliferation, differentiation, migration, invasion, and chemo resistance (Li Y et al, 2020). Recent evidence has shown that H19 is an oncogene and is overexpressed in breast, liver, endometrial, lung, cervical, and esophageal cancers (Asadi M et al, 2023). A similar pattern of H19 expression was observed in various types of leukemias, including chronic myeloid leukemia (CML) (Morlando M et al, 2015) and acute myeloid leukemia (AML) (Zhang Tj et al, 2018).

Enrollment: 96 estimated patients

Sex: All

Ages: 2 months to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Newly diagnosed ALL patients.

Exclusion criteria

• 1-Presence of other haematological disorders, history of other malignancies or relapsed ALL.

2-Patients under chemotherapy or radiotherapy.

Trial design

96 participants in 2 patient groups

ALL patients

control group free from the disease